ARCHIVES

Fidaxomicin for CDI Therapy More Cost-Effective Than Vancomycin, Study Says

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

ASCO, Komen Begin Initiative To Address Cancer Care Disparities.

October 31, 2008

In Brief: Carbone To Leave NCI for Wisconsin ACS’ Holleb Says Tobacco Industry Tries to Hide Ad Warning

October 3, 1975

NCI To Fund 29% Of Grants In 1990, With Budget Cuts

February 17, 1989

NCI Payline For Fiscal 1986 To Be 160 or 165

October 11, 1985

NCI CTEP Approved Trials For the Month of December

December 27, 2013

Simons Named CEO of Prostate Cancer Foundation.

November 17, 2006